Check 35,000+ stocks against 26 valuation models and 37 quality factors

Xvivo Perfusion AB (0RKL) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Xvivo Perfusion AB SEK 37.33, price SEK 214, upside -82.6%, quality 47 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? No
Good quality? No
Add to watchlist

Industrials · GB · ISIN SE0004840718

XP Thin data Sep 24, 2026

Xvivo Perfusion AB

0RKL · LSE

Weakest SetupStrongly overvalued and low quality.

!Fair value kr 37.33 · Strongly overvalued (−82.6%)

!Quality 47/100

!Expensive Growth (revenue 5y +35.2 %/yr)

!Thin margins · 9.9% net margin (TTM)

✓Low debt · generates free cash flow

!Narrow moat 44/100

!Evidence only low, so the estimate is less certain

26 models, one by oneBear kr 31.95 to bull kr 40.04 Growth analysisrevenue history, year by year Quality 47/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Xvivo Perfusion AB for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range kr 129.60 – kr 540.36 · fair‑value band kr 31.95 – kr 40.04 · the kr 214.40 price screens above the kr 37.33 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. It operates in Sweden; The Netherlands; The United States; Italy; North and South America; Asia/Pacific and Oceania; and internationally. Xvivo Perfusion AB (publ) was incorporated in 1998 and is headquartered in Mölndal, Sweden.

Stock analysis

Xvivo Perfusion AB (0RKL) currently trades at kr 214.40, while our model-based Fair Value estimate is kr 37.33, 82.6% below the price, so the stock looks overvalued today.

Valuation

Bull case: the DCF Models group reads highest at a median of kr 67.72 per share, and 0 of the 22 models we run sit above the kr 214.40 price.

Bear case: the Multiples group reads lowest at kr 20.01, and 22 of the 22 models stay below the price. Evidence for this calculation is low.

Scenario range: kr 31.95 (bear) to kr 40.04 (bull), the price of kr 214.40 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 47/100 (below-average quality), in the Industrials sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Xvivo Perfusion AB reported revenue of 812M SEK in FY2025 versus 258M SEK in FY2021, a compound +33.2%/yr. Reported net income was 25.2M SEK in FY2025, compounding +32.5%/yr from FY2021. FY2021 was a trough year, so the rate overstates the trend.

Key figures

Market cap 7.4B SEK (≈ $738M) · P/E ratio 11.3 · P/S ratio 0.35 · EPS (TTM) kr 0.2370 · Net margin 3.1% · Return on equity 4.1% · Return on assets (EBIT) 2.3% · Operating margin 10.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 46 out of 100 (medium confidence).

What moves the price

The share trades about 30% below its 52-week high and 33% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Industrials peers we cover trades at −24% fair-value upside, at −83%, 0RKL screens richer than that median.

Fair Value models

Bear kr 31.95 Fair Value kr 37.33 Bull kr 40.04

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (kr 0.1792 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

FCF DCF kr 34.37 kr 45.11 kr 77.22 79

Growth DCF kr 32.89 kr 47.33 kr 73.90 78

EPV kr 35.13 kr 38.42 kr 41.16 74

All 22 models by family

DCF Models

FCF DCF kr 34.37 kr 45.11 kr 77.22 79

5Y Revenue Exit kr 42.23 kr 67.72 kr 121.30 70

5Y EBITDA Exit kr 60.13 kr 103.88 kr 189.87 72

5Y P/E Exit kr 28.87 kr 47.82 kr 73.11 70

10Y Revenue Exit kr 38.51 kr 76.45 kr 102.23 66

10Y EBITDA Exit kr 51.67 kr 111.61 kr 219.32 64

10Y P/E Exit kr 30.82 kr 50.23 kr 80.91 62

Earnings-Based

Graham-Dodd kr 6.48 kr 45.20 kr 63.43 63

Lynch FV kr 16.83 kr 24.05 kr 31.26 61

PEG = 1.0 kr 16.83 kr 24.05 kr 31.26 57

EPV kr 35.13 kr 38.42 kr 41.16 74

Multiples

P/E Multiple kr 15.01 kr 20.01 kr 25.02 63

P/S Multiple kr 12.15 kr 16.20 kr 20.25 58

P/B Multiple kr 12.15 kr 16.20 kr 20.25 55

EV/EBIT kr 55.92 kr 70.90 kr 85.87 66

EV/EBITDA kr 71.28 kr 91.37 kr 111.47 67

EV/Revenue kr 43.07 kr 56.80 kr 70.54 54

Asset-Based

NCAV (Graham) kr 40.02 kr 53.63 kr 80.05 54

Growth DCF

Growth DCF kr 32.89 kr 47.33 kr 73.90 78

Economic Profit

Residual Income kr 51.62 kr 46.93 kr 44.66 71

ROIC Compounder kr 35.13 kr 38.42 kr 41.16 72

Growth Earnings

Growth-Adj P/E kr 21.56 kr 30.80 kr 40.04 67

Open the full fair value analysis →

Notify me when 0RKL reaches fair value

Put 0RKL on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 47/100

Of which business quality 49 · Market factors (momentum, volatility) 39

Profitability 25

Margins and returns on capital today

Quality Growth 20

Are margins and returns improving?

Cashflow 42

Earnings quality: real cash, not paper profit

Fin. Strength 88

Balance sheet, leverage, solvency risk

Investment 39

Disciplined investing over empire-building

Low Volatility 30

Calm price path (market factor)

Momentum 40

Price trend over the last 3–12 months (market factor)

52W Momentum 49

Distance to the 52-week high (market factor)

Net Issuance 72

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 62/100

The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Revenue growth 1 year

−1.2%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+25.1%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+35.2%

Start year 2020 (pandemic). Over 10 years: +21.0% a year

Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+22.3%

’14

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.

+27.9%

Earnings growth per share plus dividend.

Earnings per share, growth per year+27.9%

Dividend (yield on the price)0.0%

Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.27.9% vs 12.9%, picking up

Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−8% → 12%

Start year 2020 (pandemic)

Growth Forecast

A lot of optimism in the price

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

more than +80 %

Yearly growth needed for the next five years to justify today's price.

What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.

+22.4%

Yearly sales growth analysts expect, extended to five years.

After inflation (Sweden: IMF forecast 2.0% a year to 2030, 2.9% from 2016 to 2025) that is about +20.1% a year for the forecasts.

Forecast 2026 (sales)+21.8%

Forecast 2027 (sales)+27.4%

Projected 2028 (sales)+24.2%

Projected 2029 (sales)+21.0%

Projected 2030 (sales)+17.9%

0RKL screens overvalued: fair value 83% below the price. Compare with General Electric Company →

Compare Xvivo Perfusion AB with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Aerospace & Defense · 227 stocks

Beats the industry median on 8/13 measures

Overall it ranks above its industry peers.

Valuation

Quality Score 47 · Below median

Fair Value upside −88.1% · Bottom 25%

Profitability

Return on equity (TTM) 4.1% · Below median

Return on assets 3.0% · Below median

Net margin (TTM) 9.9% · Above median

Operating margin (TTM) 10.5% · Above median

Growth and dividend

Revenue growth 34.0% · Top 25%

Balance sheet

Debt / equity 0.00× · Lowest 25%

Valuation Multiplesvs Aerospace & Defense median · lower = cheaper

P/E (TTM) 11.3× · Cheapest 25%

P/B 0.37× · Cheapest 25%

P/S (TTM) 0.87× · Cheapest 25%

P/FCF 105.7× · Priciest 25%

EV/EBITDA 3.1× · Cheapest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

Weapons Defense

Similar stocks

10 more Aerospace & Defense stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
General Electric Company GE	$312.29	$92.61	−70%
RTX Corporation RTX	$185.01	$88.30	−52%
Airbus SE AIR	€185.60	€112.14	−40%
Lockheed Martin Corporation LMT	$509.25	$439.62	−14%
Howmet Aerospace Inc HWM	$230.94	$52.67	−77%
General Dynamics Corporation GD	$334.16	$274.19	−18%
Northrop Grumman Corporation NOC	$504.61	$382.98	−24%
TransDigm Group TDG	$1,116	$1,228	+10%
Thales S.A HO	€222.70	€170.99	−23%
Rheinmetall AG RHM	€956.90	€313.19	−67%

Explore undervalued stocks

More undervalued Industrials stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Xvivo Perfusion AB · Fair Value
kr 37.33 −83%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/0RKL" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Xvivo Perfusion AB · Fair Value</span><br><b style="font-size:20px">kr 37.33</b> <span style="color:#e0816f;font-weight:700;font-size:14px">−83%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Xvivo Perfusion AB Fair Value". https://www.fairvalue-calculator.com/stock/0RKL

Frequently asked questions

Is Xvivo Perfusion AB (0RKL) overvalued or undervalued?

As of Sep 24, 2026, our model estimates a fair value of kr 37.33 versus a price of kr 214.40, about −83% upside (overvalued).

What is the fair value of 0RKL?

Our model-based fair value for Xvivo Perfusion AB is kr 37.33 (as of Sep 24, 2026), built from audited fundamentals. The current price: kr 214.40.

What is the quality score of 0RKL?

Xvivo Perfusion AB has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Xvivo Perfusion AB (0RKL)?

Our model-based price target is the fair value of kr 37.33 (as of Sep 24, 2026) from 22 valuation models. Cautious scenario kr 31.95, optimistic scenario kr 40.04. It is a calculation from audited fundamentals, not an analyst target.

What is the Xvivo Perfusion AB stock forecast for 2026?

Our models put fair value at kr 37.33, about −83% upside versus a price of kr 214.40 (overvalued). Cautious scenario kr 31.95, optimistic scenario kr 40.04. The calculation is refreshed regularly with new filings.

What is the revenue of Xvivo Perfusion AB (0RKL)?

Xvivo Perfusion AB reported trailing-twelve-month revenue of about 895M SEK (latest available figure, as of Sep 24, 2026).

What growth is priced into Xvivo Perfusion AB (0RKL)?

For today's price to be fair in a discounted-cash-flow model, Xvivo Perfusion AB would have to grow free cash flow by more than 80 % per year for five years (discount rate 13.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +35.2 % per year. As of Sep 24, 2026.

What discount rate (WACC) does the fair value of 0RKL use?

Our models discount Xvivo Perfusion AB at 13.1 %: a base by market capitalisation (small), damped by beta 1.46, country premium for United Kingdom. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Xvivo Perfusion AB that is more than 80 % per year a year over ten years, using the same discount rate (13.1 %) and the same formula as our fair value.

How much growth has Xvivo Perfusion AB (0RKL) delivered so far?

Over the past 5 years revenue at Xvivo Perfusion AB grew +35.2 % a year. The price currently implies more than 80 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of Xvivo Perfusion AB (0RKL) growing?

The median revenue growth in the sector is +7.2 % a year. That is the yardstick for the growth priced into Xvivo Perfusion AB (more than 80 % per year a year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of Xvivo Perfusion AB (0RKL)?

The free-cash-flow yield on the price is 0.11 %: that much free cash flow Xvivo Perfusion AB produces per unit of market value. When it exceeds the discount rate of our models (13.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of Xvivo Perfusion AB (0RKL)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Xvivo Perfusion AB it is kr 37.33 per share (as of Sep 24, 2026), against a price of kr 214.40. It is the blended result of 22 valuation models (cash flow, earnings, asset, dividend).

Is Xvivo Perfusion AB stock overvalued or undervalued in 2026?

As of Sep 24, 2026, 0RKL trades above its calculated fair value: price kr 214.40, fair value kr 37.33, a gap of about −83% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of 0RKL?

No. The price is what the market pays today (kr 214.40); the fair value is what the company's own numbers justify (kr 37.33). For Xvivo Perfusion AB the two are kr 177.07 per share apart. That gap is exactly why we show both numbers side by side.

How much is Xvivo Perfusion AB worth?

The market values Xvivo Perfusion AB at about 7.4B SEK (market capitalisation, as of Sep 24, 2026). Per share that is kr 214.40; our models calculate a fair value of kr 37.33 per share.

What do the bullish and bearish scenarios say about 0RKL?

Our models span a range for Xvivo Perfusion AB: cautious scenario kr 31.95, base kr 37.33, optimistic kr 40.04 per share (as of Sep 24, 2026, price kr 214.40). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of 0RKL?

Xvivo Perfusion AB trades at a price-to-earnings ratio of 11.3 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of kr 37.33 is built from several models across several years. Other multiples: P/B 0.4, P/S 0.9, EV/EBITDA 3.1.

How solid is the balance sheet of Xvivo Perfusion AB (0RKL)?

Balance-sheet figures for Xvivo Perfusion AB (as of Sep 24, 2026): return on equity 4.1%, debt of 0.00 per unit of equity. They feed the Quality Score of 47/100, which measures business quality independently of the share price.

How far is 0RKL from its 52-week high?

Xvivo Perfusion AB trades at kr 214.40, about 30% below its 52-week high of kr 307.80 and 33% above the low of kr 161.56 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of kr 37.33 is for.

Which stocks are comparable to Xvivo Perfusion AB?

From the same area (Industrials) we also value General Electric Company, RTX Corporation, Airbus SE, Lockheed Martin Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Xvivo Perfusion AB stock attractive at the current price?

The data as of Sep 24, 2026: price kr 214.40, calculated fair value kr 37.33 (−83%), Quality Score 47/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of 0RKL calculated?

We run Xvivo Perfusion AB through 22 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 37.33, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.5 % above its aggregate fair value. Xvivo Perfusion AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Xvivo Perfusion AB (0RKL)?

The closing price on Oct 2, 2026 was kr 214.40. Our model-based fair value is kr 37.33, about −83% upside (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Xvivo Perfusion AB right now?

The price sits above even our optimistic bull case (kr 40.04). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (47/100) and above fair value, neither a clear bargain nor a standout compounder.

Where does the earnings growth of Xvivo Perfusion AB (0RKL) come from?

Earnings per share at Xvivo Perfusion AB grew +37.0 % a year from 2014 to 2025. Broken into its drivers: revenue per share +18.3 %, EBIT margin +5.3 %, tax rate +3.1 %, residual (interest, one-offs) +6.7 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Xvivo Perfusion AB

How large is the market capitalisation of Xvivo Perfusion AB (0RKL)?

The market capitalisation of Xvivo Perfusion AB is 7.4B SEK (≈ $738M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Xvivo Perfusion AB (0RKL)?

The price-to-sales ratio of Xvivo Perfusion AB is 0.35 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Xvivo Perfusion AB (0RKL)?

Earnings per share at Xvivo Perfusion AB are kr 0.2370 (price ÷ EPS = P/E 11.3). Earnings per share over the last twelve months: total profit spread across every single share.

What is the net margin of Xvivo Perfusion AB (0RKL)?

The net margin of Xvivo Perfusion AB is 3.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Xvivo Perfusion AB (0RKL)?

The return on equity (ROE) of Xvivo Perfusion AB is 4.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Xvivo Perfusion AB (0RKL)?

On an EBIT basis the return on assets of Xvivo Perfusion AB is 2.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Xvivo Perfusion AB (0RKL)?

The operating margin of Xvivo Perfusion AB is 10.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Xvivo Perfusion AB (0RKL)?

Revenue at Xvivo Perfusion AB is growing +34.0% versus a year earlier (3y avg +25.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Xvivo Perfusion AB (0RKL)?

Earnings per share at Xvivo Perfusion AB are growing +935% versus a year earlier. How much earnings per share grew versus a year earlier.

How much net cash does Xvivo Perfusion AB (0RKL) hold?

Xvivo Perfusion AB holds more cash than debt, 54.2M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.

Free · no account needed

Watch Xvivo Perfusion AB in the live analysis

One click puts Xvivo Perfusion AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.